Hyderabad-based consumer AI startup Equal AI has raised $30 Mn in a Series B funding round co-led by Prosus Ventures and Tomales Bay Capital, as investors continue to back AI-native consumer ...

Expert at the Conservancy of Southwest Florida topped their own record for the most tonnage of Burmese python removed from the wildlife.

To stop this from spiraling, Anthropic calls for a verifiable, industry-wide pause—a kind of AI arms-control treaty—because ...

Sakana AI has opened a Recursive Self-Improvement Lab to test whether AI systems can help redesign and optimize future AI ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...

In the world of computer science, the ability to repeat a set of instructions is a fundamental building block. Two primary paradigms exist to achieve this repetition: iteration and recursion. While ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...